The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHOC 2022 | Signaling pathways involved in drug resistance in MPNs
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into signaling pathways involved in drug resistance in myeloproliferative neoplasms (MPNs), drawing focus on the pathways involved in resistance to ruxolitinib. Dr Lucchesi also comments on agents that may be combined with ruxolitinib, including navitoclax and parsaclisib. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
